Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
Código da empresaCSTL
Nome da EmpresaCastle Biosciences Inc
Data de listagemJul 25, 2019
CEOMaetzold (Derek J)
Número de funcionários761
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 25
Endereço505 S Friendswood Drive
CidadeFRIENDSWOOD
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal77546
Telefone18667889007
Sitehttps://castlebiosciences.com/
Código da empresaCSTL
Data de listagemJul 25, 2019
CEOMaetzold (Derek J)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados